Michael Sticherling
0000-0001-9396-3938
8 papers found
Refreshing results…
SCLE manifestation after mRNA COVID‐19 vaccination
Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*
Genetic analysis of MPO variants in four psoriasis subtypes in patients from Germany
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score
An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial
Missing publications? Search for publications with a matching author name.